Background Although chest X-rays (CXRs) are widely used, diagnosing mitral stenosis (MS) based solely on CXR findings remains ...
All in all, PHAT has 6 recent analyst reviews that break down into 5 Buys and 1 Hold, giving the stock a Strong Buy consensus rating. The shares are priced at $17.66 and have an average price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback